Response to “Comments on ‘Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43’ ” [Med. Phys. <b>22</b>
, 209-234 (1995)]

Nath, Ravinder

doi:10.1118/1.597556

Cited by 7 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 5 demonstrates the OSLD’s independence to dose rate by showing the relationship between OSLD response and the dose rate, with overall R 2 of 0.999. Measurements agreed well with the theoretical dose as calculated using TG-43 and inverse-square factor calculated using the positions summarized previously in Section II.A, with a maximum error of 3.9% relative to the measurements (Nath et al, 1995). The computational output factors calculated by Oncentra agreed well, with a maximum error of 2.3% relative to the measurements.…”

Section: Resultssupporting

confidence: 80%

“…AccuBoost ® procedures use an HDR Ir-192 source in this applicator to deliver radiation to breast lesions (Rivard et al, 2009). To minimize the anisotropy of an HDR source, the applicator positions the source’s long axis normal to the applicator’s central axis (Nath et al, 1995, 1997). The applicator has been shown to be large enough for a high dose rate, yet small enough to approximate as a point source.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy

Tien¹,

Ebeling²,

Hiatt³

et al. 2012

Front. Oncol.

View full text Add to dashboard Cite

Purpose: The objective was to determine whether optically stimulated luminescent dosimeters (OSLDs) were appropriate for in vivo measurements in high dose rate brachytherapy. In order to make this distinction, three dosimetric characteristics were tested: dose linearity, dose rate dependence, and angular dependence. The Landauer nanoDot™ OSLDs were chosen due to their popularity and their availability commercially. Methods: To test the dose linearity, each OSLD was placed at a constant location and the dwell time was varied. Next, in order to test the dose rate dependence, each OSLD was placed at different OLSD-to-source distances and the dwell time was held constant. A curved geometry was created using a circular Accuboost® applicator in order to test angular dependence. Results: The OSLD response remained linear for high doses and was independent of dose rate. For doses up to 600 cGy, the linear coefficient of determination was 0.9988 with a response of 725 counts per cGy. The angular dependence was significant only in “edge-on” scenarios. Conclusion: OSLDs are conveniently read out using commercially available readers. OSLDs can be re-read and serve as a permanent record for clinical records or be annealed using conventional fluorescent light. Lastly, OSLDs are produced commercially for $5 each. Due to these convenient features, in conjunction with the dosimetric performance, OSLDs should be considered a clinically feasible and attractive tool for in vivo HDR brachytherapy measurements.

show abstract

Section: Resultssupporting

confidence: 80%

Section: Methodsmentioning

confidence: 99%

Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy

Tien¹,

Ebeling²,

Hiatt³

et al. 2012

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Due to radiation safety considerations, however, 226 Ra has largely been replaced by other radionuclides (33). Currently, the majority of interstitial brachytherapy treatments are delivered using different radioactive sources, such as 192 Ir, 103 Pd and 125 I (33). …”

Section: Discussionmentioning

confidence: 99%

“…103 Pd decays with a half-life of 17.0 days and emits photons with an average energy of 21–30 keV. A 103 Pd source is similar in size and encapsulation to 125 I sources (33). Although it also offers the practical advantage of low energy, reducing the dose to surrounding organs and minimizing shielding requirements, the difference of the half-lives between 103 Pd (17 days) and 125 I (61 days) is marked (33).…”

Section: Discussionmentioning

confidence: 99%

“…A 103 Pd source is similar in size and encapsulation to 125 I sources (33). Although it also offers the practical advantage of low energy, reducing the dose to surrounding organs and minimizing shielding requirements, the difference of the half-lives between 103 Pd (17 days) and 125 I (61 days) is marked (33). In addition, 125 I has been in practical use for longer than 103 Pd (33).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CT-guided 125I seed implantation for inoperable retroperitoneal sarcoma: A technique for delivery of local tumor brachytherapy

Yang

Guo

Lan

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Radical surgery is currently the first treatment of choice for retroperitoneal soft tissue sarcoma (RSTS). However, the prognosis of RSTS remains poor due to ineffective local control and a high incidence of metastasis after surgical resection. Brachytherapy has been shown to safely provide local radiotherapy for numerous types of cancer when used alone or in combination with surgical resection, but has not been well characterized in the management of RSTS. The aim of this study was to evaluate CT-guided 125I seed implantation for local control and pain relief in the treatment of inoperable RSTS. A total of 23 patients with RSTS were treated with 125I implantation. Pain was assessed using a visual analog scale. Other endpoints were evaluated via computed tomography scan or phone call/e-mail records. The occurrence of complications was assessed preoperatively (baseline) and during postoperatively follow-up or until patient succumbed. All patients were successfully treated with 125I implantation. A mean number of 70.87 radioactive seeds were applied in each patient. During the follow-up, two patients were unaccounted for, local recurrence occurred in three patients, five succumbed and complications were observed in sixteen. The patient's VAS score changed from 7.4 preoperatively to 7.6, 2.3, 2.0, 1.2, 1.5, 1.4 and 2.5 at 24 h, 1, 3, 6, 12, 24 and 36 months after the procedure, respectively. Good local control and significant pain relief after 125I seed implantation was observed in patients with inoperable RSTS. Thus, the present results suggest that this method could be an effective treatment option for patients with inoperable RSTS.

show abstract

RSC: Dosimetry in high-dose-rate brachytherapy with a radio-fluorogenic gel dosimeter

Inoue

Watanabe

Maeyama

et al. 2022

J. Phys.: Conf. Ser.

View full text Add to dashboard Cite

A nanoclay-based radio-fluorogenic gel (NC-RFG) was used to verify the source position and dose distribution in high-dose-rate (HDR) brachytherapy. The dose response confirmed linearity up to 60 Gy. The source position could be detected with an accuracy of ≤0.3 mm, and the dose distribution near the Ir-192 source showed good agreement with the Monte Carlo simulation. NC-RFG can be expected to be a quality assurance tool suitable for the evaluating the dose distribution in HDR brachytherapy.

show abstract

Response to “Comments on ‘Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43’ ” [Med. Phys. 22 , 209-234 (1995)]

Cited by 7 publications

References 0 publications

Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy

Optically Stimulated Luminescent Dosimetry for High Dose Rate Brachytherapy

CT-guided 125I seed implantation for inoperable retroperitoneal sarcoma: A technique for delivery of local tumor brachytherapy

RSC: Dosimetry in high-dose-rate brachytherapy with a radio-fluorogenic gel dosimeter

Contact Info

Product

Resources

About